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The 18 kDa peripheral benzodiazepine receptor (PBR) can be labelled by benzodiazepines, uch as Ro54864, and isoquinoline carboxamides such 
as PK11195. These two compounds are reversible competitive inhibitors of each other. However, while the binding affinity of Ro5-4864 varies 
enormously across species, PK11195 always displays high affinity, suggesting that their binding domains are overlapping but not identical. We 
report here that recombinant human and bovine PBR produced in yeast, a microorganism devoid of endogenous PBR, can be labelled with 
[‘H]PKll195, but only the human receptor can be labelled with [3H]Ro54864. Furthermore, we identified, through the binding analysis of 
human-bovine chimaeric receptors, a region near the C-terminal end of the PBR, with only five non-conserved amino acids between human and 
bovine sequences, as responsible for the difference in high affinity binding of Ro5-4864 to the two receptors. 
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1. INTRODUCTION 
The psychoactive benzodiazepine (Bz) drugs exert 
sedative, anxiolytic and anticonvulsant effects through 
the central benzodiazepine receptor associated with the 
GABA-regulated chloride channels located in the cen- 
tral nervous system [l]. Bz also interacts with a second 
receptor originally described in rat peripheral tissues 
and designated as the peripheral benzodiazepine recep- 
tor (PBR) [2]. This receptor is expressed in almost all 
tissues and abundantly in steroid-producing cells [3,4]. 
PBR is a small protein (18 kDa) located mainly in the 
outer membrane of the mitochondria [5], but it is also 
present on the membrane of erythrocytes and adrenal 
cells [6,7]. A physiological role for the mitochondrial 
PBR has been demonstrated in adrenocortical cells 
[8,9]. A more general regulatory role has been suggested 
for the PBR present in the glial cells in the brain [lo], 
but no clear function has been ascribed either to the 
mitochondrial receptor present in non steroid-produc- 
ing cells, or to the cell membrane receptor. The cDNAs 
for the rat [l 11, bovine [12], and human [13] proteins 
have been recently cloned and the deduced amino acid 
sequences how that the 18 kDa PBR is a hydrophobic 
protein with five potential transmembrane regions. 
PBR can be labelled not only with Bz, such as Ro5- 
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4864, but also with isoquinoline carboxamides (IQC), 
such as PK11195. In fact, IQC, which are structurally 
different from Bz, have much greater selectivity for PBR 
than for the central benzodiazepine receptor [14]. Al- 
though Bz and IQC are able to displace each other from 
PBR [l l-14,16], there is evidence that suggests that the 
binding domains of the two compounds are not identi- 
cal. For example, Bz and IQC binding to rodent recep- 
tors can be differentially perturbed by several enzymatic 
or chemical modifications [17-191. Furthermore, it has 
been shown that high affinity binding for the IQC 
PK11195 is conserved across species, while marked dif- 
ferences have been described for the binding of the Bz 
Ro5-4864 [20]. It is difficult to rule out that other pro- 
teins in the membrane nvironment may be responsible 
for this Ro5-4864 binding behaviour since it has been 
shown that several proteins are closely associated to the 
18 kDa PBR [21,22]. The present study examines the 
molecular basis of the differences in the Bz Ro54864 
binding to the human and bovine 18 kDa PBR. We 
constructed chimaeric receptors with segments of the 
human PBR, which binds PKl 1195 and Ro5-4864 [ 131, 
and segments of the bovine receptor which binds only 
PK11195 [12]. Then, the human, bovine, and chimaeric 
receptors were produced in yeast, thus providing a ho- 
mogeneous cellular environment devoid of endogenous 
PBR [23], and analysed for binding of PK11195 and 
Ro5-4864. Our results show that the differential bind- 
ing of Ro54864 to the human and bovine receptors is 
due to amino acid differences between the two PBRs; 
that Bz and IQC binds to overlapping but not identical 
sites on the PBR; and that a small sequence near the 
305 
Volume 335, number 3 FEBSLETTERS December 1993 
C-terminal end of the molecule is involved in the bind- 
ing of Ro54864 but not of PK11195. 
2. MATERIALS AND METHODS 
2.1. Bacteria and yeast strains 
Escherichia coli strains were TGl (hsdS, proAB, lacZX174, {F 
pro+, DM15)) and S17-1 (recA, thi, pro, h.sdR [RP4 : 2-Tc :: Mu ; 
Kn :: Tn7] [24]. C13ABYS86 (MATa, ura3, leu2, his3, pral, prbl. prcl, 
cpsl) is a multiprotease-deficient strain of Saccharornyces cerevisiae 
obtained from D. Wolf [25]. Bacterial strains were grown in LB me- 
dium containing 100 ,ug/ ml ampicilline, or in 2YT [26]. Yeast strains 
were grown in complex YP (1% yeast extract, 2% bacto-peptone) or 
minimal YNB (0.67% yeast nitrogen base) media supplemented with 
either 2% glucose or 2% glycerol and 2% galactose. 
2.2. Pkwnid constructions, yeast transformation andE. coli-S. cerevis- 
iae DNA transfer 
All the yeast expression vectors used throughout this study are 
derived from pEMR614 [23]. The non-translated sequences located at 
the 3’-end of the PBR cDNA were deleted from pEMR614 to yield 
pEMR763. Plasmid pEMR780 differed from pEMR763 by the addi- 
tion of the RP4-derived 760 bp fragment hat contained oriT. This 
small fragment, which flanks the 3’-end of the PGK terminator in 
pEMR780 (Fig. l), is required for RP4-encoded transacting proteins 
to direct the in vivo transfer of the shuttle plasmid from a E. coli donor 
to a Saccharomyces cerevisiae recipient, namely S17-1 and 
C13ABYS86, respectively. A synthetic bovine PBR gene was con- 
structed by standard methods [27], the published sequence [12] being 
slightly modified to introduce restriction sites found in the human 
sequence to facilitate the obtention of chimaeras (Fig. 2B). A trun- 
cated human receptor S-II was obtained by introducing a stop codon 
after arginine-156 by site directed mutagenesis (Amersham). 
For the transkingdom-conjugation mid-exponentially growing 
donor cells were harvested and resuspended in 10 mM MgSO, to a 
final density of 2 x 109/ml. Recipient c13ABYS86 cells were grown 
overnight in YPG, pelleted and resuspended in 10 mM MgSO, to 10’ 
cells/ml. Donors and recipient cells were mixed in a ratio of 1:l on a 
HP25 millipore filter, incubated on YPG-agar plates for 8 to 16 h, 
resuspended in 10 mM MgSO, and tinally spread onto selective 
YNBG medium at 30°C. Exconjugants were identified by their ability 
to form colonies on a pyrimidine-free or a leucine-free growth me- 
dium. 
2.3. Recombinant receptor expression, subcellular fractionation, and 
binding of rH]PKl I1 95 and [3H]Ro5-4864 
Yeast transformants were grown in YNBG supplemented with 0.5% 
casaminoacids for 16 h. Cells were washed and resuspended in YP 
medium containing galactose and glycerol. Cells were then grown at 
30°C overnight. Mitochondria were isolated as described [28], and 
used for the binding experiments. 
Saturation experiments with [31-IlPKl 1195 (66.0 Ci/mmol, CEA, 
Gif-stir-Yvette, France) or with [‘H]Ro54864 (63.0 Cilmmol, CEA, 
Gif-sur-Yvette, France) were performed on the mitochondrial fraction 
of the cell-free extracts as previously described 122,231. Specific bind- 
ing was calculated as the difference between the binding in the absence 
and in the presence of unlabeled PKll195 (Sanofi) or Ro54864 
(Sanofi); non-specific binding represented less than 10% of total bind- 
ing. Scatchard analysis was performed as previously described [23]. 
3. RESULTS 
Human and bovine PBRs are 169 amino acid proteins 
with 5 putative transmembrane domains (Fig. 2A). Re- 
combinant human PBR expressed in yeast binds the 
IQC [3H]PK1 1195, and the Bz [3H]Ro5-4864, while the 
recombinant bovine PBR expressed in the same system 
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Fig. 1. Structure of pEMR780. The pEMR780 plasmid (8515 bp) is 
derived from the already described pEMR614 [24]. This plasmid con- 
tains the ampicillin-resistance gene of pBR322 (amp), the defective 
LEU-a gene cloned inside the @ fragment hat contains the origin of 
replication and the c&acting STB locus, the URA3 marker and the 
PBR-expression cassette. 
binds only the IQC (Table I). To identify the regions of 
the human PBR responsible for the high affinity binding 
of benzodiazepines we carried out a systematic ex- 
change of segments of the human with the correspond- 
ing bovine PBR segments (Fig. 2B). The resulting 
chimaeric receptors were expressed in yeast, and a mito- 
chondrial enriched fraction was tested for binding with 
[3H]PKl 1195 and [3H]Ro5-4864. The first two mutants 
constructed, C-I and C-II (Fig. 2B) combined the N- 
and C-terminal halves of the human sequence with the 
C- and N-terminal halves of the bovine receptor se- 
quences. Scatchard analysis of the saturation curves 
showed that both C-I and C-II chimaeric receptors were 
Table I 
Affiity of the chimeric human-bovine and deleted human PBR for 
the isoquinoline carboxamide PK11195 and the benzodiazepine 
Ro5-4864 
Receptor Ecd (nM) 
PK11195 Ro5-4864 
wh 
Wb 
C-I 
C-II 
C-III 
C-IV 
c-v 
S-II 
hl-169 
bl-169 
bl-88-h89-169 
hl-88b89-169 
hl-88-b89-143-h144-169 
hl-143-b144-169 
bl-143-h144-169 
hl-156 
s+ 2 
18f 8 
13f 5 
22 f 10 
10f 4 
5+ 3 
14f 4 
9f 7 
14 * 7 
>200 
22 f 9 
>200 
14 + 4 
> 200 
13 + 3 
12 f 5 
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W-b 
08-09 
C-l - 1 
C-II 
143-144 
C-III 1 
C-IV ’ 
c-v 
156 
S-II 1 I 
145 150 155 
human . . . LAFATTLNYCVWR.. 
bovine . . . - - --GM---RM-Q.. 
Fig. 2. (A) Putative transmembrane r gions (TM) deduced from the 
hydrophatic profile of the human and bovine PBR sequences. (B) 
Recombinant chimaeric receptors (C-I to C-V) constructed with seg- 
ments from the human (Wh) and bovine (Wb) receptors; and short 
(S-II) form of the human receptor. The restriction sites PvaII and SjiI 
used for the gene constructions are indicated for the Wh and Wb. (C) 
Amino acid differences between the human and bovine PBR in the 
region 144-156 of the sequences. 
able to bind PK11195 with affinities similar to those 
shown by the wild type human (Wh) and bovine (Wb) 
receptors. However, only the C-I receptor (bovine- 
human) was able to bind Ro5-4864, the C-II receptor 
(human-bovine) having lost the capacity to recognise 
this ligand (Table I). These results indicated that some 
of the 21 residues that differ in the human and bovine 
C-terminal 80 amino acid sequence are necessary for the 
binding of Ro54864 but not of PK11195. 
Subsequent chimaeric receptors were designed to in- 
vestigate whether the fist or second part of the C- 
terminal 80 amino acid sequence was involved in the 
binding of Ro5-4864. Scatchard analysis of the satura- 
tion curves of the C-III receptor, where the human se- 
quence 89-143 was replaced by the corresponding bo- 
vine one, showed that it behaved as the Wh receptor. 
Both [3H]PK11195 and [3H]Ro5-4864 labelled the 
chimaeric receptor with & of 10 and 20 nM, respec- 
tively, indicating that the 10 amino acid differences be- 
tween human and bovine receptors located in this re- 
gion are irrelevant for the binding of Bz. Analysis of 
C-IV, where the last 26 amino acids of the human se- 
quence were replaced by the corresponding bovine se- 
quence, showed a Kd of 5 nM for PK11195, but Ro5- 
4864 was not able to bind to this receptor. Thus, C-IV 
behaved like the Wb receptor. The human and bovine 
26 amino acid C-terminal sequences differ in 11 resi- 
dues. Of those 11, 6 are not essential either for the 
binding of Bz or for IQC, since a recombinant receptor 
lacking the last 13 amino acids (S-II) could be labelled 
with [31-IjPK11195 as well as [3H]Ro5-4864. As seen in 
Table I, IQC and Bz bound to S-II with a Kd of 9 nM 
and 12 nM, respectively. Thus, the candidate amino 
acids that make possible the binding of Ro5-4864 to the 
human receptor can be reduced to the five residues that 
differ in the 144156 portion of the protein. These 
amino acids are: threonine- 148, threonine- 149, cysteine- 
153, valine-154, and arginine-156, that in the bovine 
sequence are replaced by glycine, methionine, arginine, 
methionine, and glutamine, respectively (Fig. 2C). To 
investigate if these residues could confer Ro54864 
binding capacity we constructed C-V, a chimaeric bo- 
vine receptor in which those C-terminal amino acids 
were replaced by the corresponding ones in the human 
sequence. Analysis of the saturation experiments of the 
recombinant receptor showed that those changes were 
sufficient o confer the capacity to bind Ro5-4864 to the 
bovine receptor, while the capacity to bind PK11195, as 
expected, was not affected (Table I). 
4. DISCUSSION 
We have presented here a study aimed at the identifi- 
cation of the molecular basis of the differential binding 
behaviour of Ro54864 to the PBR across species. 
When expressed in yeast, a cell devoid of endogenous 
PBR, the human PBR can be labelled with PK11195 
and Ro5-4864, but the bovine PBR can be labelled only 
with Ro5-4864, suggesting that the non-conserved 
amino acids between both sequences are involved in the 
binding of the Bz. To test this hypothesis, and identify 
those amino acids, we constructed human-bovine 
chimaeric receptors. The chimaeric receptors were ex- 
pressed in yeast and analysed for binding with 
[3H]PK1 1195 and [3H]Ro54864. The results pointed to 
the 26 C-terminal residues as responsible for the binding 
of Ro5-4864 to the human receptor. We confirmed that 
this region was responsible for the differential binding 
of Ro5-4864 to the human and bovine receptors, by 
constructing a bovine receptor with the human C-termi- 
nal 26 amino acids. This chimaera indeed behaved as 
the Wh receptor. However, since the last 13 residues of 
the receptor are not essential for the binding of the Bz, 
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the region was narrowed down to 13 residues, of which 
only five are different between the human and bovine 
molecules. Those non-conserved amino acids are thre- 
onine-148, threonine-149, cysteine-153, valine-154, and 
arginine-156 in the human sequence, that are replaced 
by glycine, methionine, arginine, methionine, and glu- 
tamine, respectively, in the bovine sequence. Interest- 
ingly, the rat PBR, which binds IQC and Bz with high 
affinity, shares the threonine-148, valine-154, and argin- 
ine-156, with the human sequence. Thus, we speculate 
that one or more of these residues may be the key to the 
binding of Ro5-4864 to the human PBR and work is in 
progress to test this hypothesis. It should also be noted 
that all the chimaeric receptors bound PK11195 with 
high affinity, suggesting that the modifications do not 
alter either the targeting of the receptor to the mito- 
chondrial membrane or the membrane topology of the 
receptor. Although other mitochondrial membrane pro- 
teins closely associated with the 18 kDa protein [21,22] 
may contribute to the binding properties of PBR, our 
results show that the Bz and IQC binding differences 
observed between the human and bovine PBR can be 
attributed to the non-conserved amino acids between 
the two sequences. Thus, since PK11195 and Ro5-4864 
displace each other from the human receptor [24,28] 
and since our results clearly show that certain amino 
acids are implicated only in the binding of Ro54864, 
an appropriate model is that of two overlapping sites, 
as previously suggested [17,18]. However, an alternative 
model of two different conformational states, one that 
binds preferentially IQC and the other Bz [18], cannot 
be excluded. We have previously reported, using 
[3H]PK14105, a photoaffinity probe derived from 
PK11195, that amino acids in the N-terminal region of 
the human PBR were involved in the binding of isoqui- 
nolines [13]. Those results, together with the ones de- 
scribed here, suggest hat the N- and C-terminal regions 
of the molecule may be closely located and exposed to 
the cytoplasm once it is inserted in the mitochondrial 
membrane. We recently described a tridimensional 
model, based on molecular dynamic simulations, in 
which the putative 5 membrane regions delimited a pore 
[30]; in that model the first and fifth transmembrane 
regions are close. Interestingly, the amino acids identi- 
fied in this work as essential for the binding of Ro5- 
4864 are in the interface between the membrane and the 
cytoplasm in the models based on the hydropathic pro- 
file of PBR [30,31]. A better understanding of the Bz 
and IQC binding sites on the PBR may contribute to the 
synthesis of new specific ligands for one or the other 
binding site that should help to a better understanding 
of the structure and physiological function of this recep- 
tor. 
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